Results 51 to 60 of about 766 (168)

Blast and Bursts: Unveiling Splenic Rupture in Blastic Plasmacytoid Dendritic Cell Neoplasia. [PDF]

J Community Hosp Intern Med Perspect
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a rare hematologic cancer, accounting for less than 1% of acute leukemias in the U.S. Diagnosis involves detecting markers like CD123, CD4, CD56, TCL1, and TCF4.
Hassan A, Simpson M, Jiwani R, Arrigo A, Nisarga P, Esan OA, Koget A.   +6 more
europepmc   +2 more sources

A Case of Cutaneous Blastic Plasmacytoid Dendritic Cell Neoplasm Treated With a Bcl-2 Inhibitor

, 2021
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive primary cutaneous lymphoma characterized by transformed plasmacytoid dendritic cells that overexpress interleukin-3 receptor subunit alpha (IL3RA) also known as CD123.
Egger, Andjela, Coello, Diana, Kirsner, Robert S, Brehm, Julia Escandon   +3 more
core   +1 more source

Care Optimization for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm Receiving Tagraxofusp. [PDF]

J Adv Pract Oncol
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive, orphan hematologic malignancy that expresses CD123 and frequently presents in skin, bone marrow, blood, and viscera. Tagraxofusp is a first-in-class CD123-targeted therapy and the only US-approved drug to treat BPDCN.
Faysman K, Rubin J, Lubas A, Kujawa T, Hinojosa G, Marx KR, Katsetos J, Galinsky IA.   +7 more
europepmc   +3 more sources

Real-world evidence on tagraxofusp for blastic plasmacytoid dendritic cell neoplasm – collected cases from a single center and case reports

Frontiers in Oncology
IntroductionBlastic plasmacytoid dendritic cell neoplasia (BPDCN) is a rare, aggressive hematologic malignancy. Until recently, the only curative treatment consisted of intensive chemotherapy, followed by hematopoietic cell transplantation (HCT) in ...
Philipp Faustmann, Jan C. Schroeder, Lucas Mix, Lennart Harland, Andreas Riedel, Wichard Vogel, Claudia Lengerke, Stefan Wirths   +7 more
doaj   +1 more source

Pseudomonas Exotoxin-Based Immunotoxins: Over Three Decades of Efforts on Targeting Cancer Cells With the Toxin

Frontiers in Oncology, 2021
Cancer is one of the prominent causes of death worldwide. Despite the existence of various modalities for cancer treatment, many types of cancer remain uncured or develop resistance to therapeutic strategies.
Seyed Mehdi Havaei, Marc G. Aucoin, Ali Jahanian-Najafabadi   +2 more
doaj   +1 more source

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in an Elderly Female: A Rare Rash

, 2023
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a rare hematologic malignancy derived from type 2 Dendritic cells (immature Plasmacytoid dendritic cells).
Charmee Vyas, Vishakha Sirpal, Husam Bader, Khalid, Farhan, Vyas, Charmee, Al-Alwan, Ahmad, Bader, Husam, Ahmad Al-Alwan, Sirpal, Vishakha, Farhan Khalid   +9 more
core   +1 more source

Recent developments in the treatment of blastic plasmacytoid dendritic cell neoplasm

Therapeutic Advances in Hematology, 2019
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a clinically aggressive hematologic malignancy derived from precursors of dendritic cells and involves most frequently the skin, bone marrow and lymph nodes. Diagnosis depends upon identification of
Minas P. Economides, Marina Konopleva, Naveen Pemmaraju   +2 more
doaj   +1 more source

Cutaneous involvement by myeloid leukaemias: challenging cases with important implications

Histopathology, EarlyView.
Myeloid leukaemias and precursors involving the skin are often challenging to diagnose with varied and overlapping clinical and histopathologic features. Nonetheless, they are critical for pathologists to recognize and accurately classify. This review discusses the clinical, histopathological and genetic features of myelodysplasia cutis (A) and ...
Alexandra C. Hristov
wiley   +1 more source

Histone deacetylase inhibitors as venetoclax‐sensitising partners in acute myeloid leukaemia: Mechanisms, pharmacology and translational perspectives

British Journal of Pharmacology, Volume 183, Issue 21, Page 6261-6290, November 2026.
Abstract Venetoclax combined with hypomethylating agents has improved treatment for older or unfit patients with acute myeloid leukaemia (AML), but resistance and relapse remain common. This review analyses the rationale for combining venetoclax with inhibitors of histone deacetylase (HDAC).
Jaebok Lee, Marc Diederich
wiley   +1 more source

Blastic Plasmacytoid Dendritic Cell Neoplasm, from a Dermatological Point of View [PDF]

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematological malignancy derived from the precursors of plasmacytoid dendritic cells.
Cosimo Di Raimondo, Claudia Paganini, Marco Galluzzo, Luca Bianchi, Flavia Lozzi, Pier Paolo Di Domenico, Elena Campione   +6 more
core   +2 more sources